BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 65.38% | 45.93% | 36.21% | 25.73% | -129.74% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.59% | -60.61% | -44.64% | -34.31% | 1,283.50% |
| Change in Net Operating Assets | -17.72% | 52.71% | 11.24% | 19.66% | -48.61% |
| Cash from Operations | 33.46% | 65.25% | 51.43% | 36.78% | 44.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 89.91% | 32.50% | 18.26% | -19.09% | -26.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 92.62% |
| Cash from Financing | 90.60% | 31.91% | 15.50% | -21.37% | -15.78% |
| Foreign Exchange rate Adjustments | 106.51% | 84.25% | -126.32% | -119.05% | -156.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,414.49% | 255.04% | 1,190.12% | 70.91% | 95.02% |
